Electronic voting

Announcement of solicitation of consents by SODEXO

Retrieved on: 
Monday, July 3, 2023

The Consent Solicitation is being made on the terms and subject to the conditions set out in the Consent Solicitation Memorandum dated July 3, 2023 (the “Consent Solicitation Memorandum”).

Key Points: 
  • The Consent Solicitation is being made on the terms and subject to the conditions set out in the Consent Solicitation Memorandum dated July 3, 2023 (the “Consent Solicitation Memorandum”).
  • Capitalised terms used in this announcement but not defined have the meanings given to them in the Consent Solicitation Memorandum.
  • In addition, Bondholders may contact the Solicitation Agents for information at their telephone number and email address set out on the back cover page of the Consent Solicitation Memorandum.
  • The Consent Solicitation Memorandum, each Fiscal Agency Agreement and each Notice of Meeting are available for viewing on the Consent Website.

Broadridge Teams with SLIB to Deliver French Market Voting Solution for Global Investors

Retrieved on: 
Tuesday, November 29, 2022

LONDON and PARIS, Nov. 29, 2022 /PRNewswire/ -- Extending their joint strategic commitment to modernise and enhance shareholder voting in the French market, Broadridge Financial Solutions, Inc. (NYSE: BR) and SLIB, a leading software editor for electronic voting and securities services based in France, today announced the go-live of their joint end-to-end global voting solution.

Key Points: 
  • LONDON and PARIS, Nov. 29, 2022 /PRNewswire/ -- Extending their joint strategic commitment to modernise and enhance shareholder voting in the French market, Broadridge Financial Solutions, Inc. (NYSE: BR)and SLIB, a leading software editor for electronic voting and securities services based in France, today announced the go-live of their joint end-to-end global voting solution.
  • "Broadridge remains firmly committed to enabling greater levels of shareholder engagement across markets globally," said Demi Derem, General Manager of Broadridge's International Investor Communication Solutions.
  • The announcement represents a significant addition to the cross-border proxy voting service for France-based investors that hold international shares, launched by Broadridge and SLIB in December 2021.
  • "With Broadridge, the leading global proxy voting provider, as our strategic partner, we can now offer intermediaries a comprehensive and efficient ecosystem, that combines support for international investors in French listed companies, and for French investors in foreign companies."

Euroclear Investments - Announcement of Consent Solicitations

Retrieved on: 
Thursday, February 24, 2022

This announcement must be read in conjunction with the Consent Solicitation Memorandum.

Key Points: 
  • This announcement must be read in conjunction with the Consent Solicitation Memorandum.
  • Capitalised terms used in this announcement have the meanings given in the Consent Solicitation Memorandum.
  • of the principal amount of the relevant Series of Notes that are the subject of such Electronic Voting Instruction (each such consent fee in relation to a Series of the Notes, a "Consent Fee").
  • Eligible Noteholders are advised to read carefully the Consent Solicitation Memorandum for full details of, and information on the procedures for participating in, the Consent Solicitations.

Broadridge and SLIB Joint SRD II Proxy Voting Solution for French Market is NOW LIVE

Retrieved on: 
Thursday, December 9, 2021

LONDON and PARIS, Dec. 9, 2021 /PRNewswire/ --Global Fintech leader Broadridge Financial Solutions, Inc. (NYSE:BR), and SLIB, a leading-edge software vendor in electronic voting and securities services based in France, have announced the live operational running of their joint cross-border proxy voting solution.

Key Points: 
  • LONDON and PARIS, Dec. 9, 2021 /PRNewswire/ --Global Fintech leader Broadridge Financial Solutions, Inc. (NYSE:BR), and SLIB, a leading-edge software vendor in electronic voting and securities services based in France, have announced the live operational running of their joint cross-border proxy voting solution.
  • Unique in the French market, the solution enables intermediaries - including banks, brokers and wealth managers that serve France-based investors - to meet their new, mandatory obligations to support voting for European shareholder meetings under the updated Shareholder Rights Directive (SRDII).
  • SLIB is the leading software vendor in register management & electronic voting, risk and post-trade markets.
  • SLIB is also Votaccess Operator, the cornerstone of Electronic Voting for Paris Stockexchange issuers and Account Keepers, delivering General Meetings notifications and collecting Digital Votes.

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Wednesday, August 4, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Wednesday, August 4, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Tuesday, August 3, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Friday, July 30, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Friday, July 30, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO

Form 8.3 - The Vanguard Group, Inc.: UDG Healthcare plc

Retrieved on: 
Wednesday, July 28, 2021

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.

Key Points: 
  • Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced.
  • If none, this should be stated.
  • Is a Supplemental Form 8 attached?
  • (Note 9) NO